Published in Nat Rev Rheumatol on November 15, 2011
CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature (2016) 2.53
Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) (2014) 1.34
T cell immunity and cardiovascular metabolic disorders: does metabolism fuel inflammation? Front Immunol (2012) 0.90
Effect of Drug Therapy on Net Cholesterol Efflux Capacity of High-Density Lipoprotein-Enriched Serum in Rheumatoid Arthritis. Arthritis Rheumatol (2016) 0.78
Advances in psoriasis treatment: experts comment on recent developments. P T (2013) 0.75
What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis? Arthritis Res Ther (2016) 0.75
The Role of Efferocytosis in Atherosclerosis. Circulation (2017) 0.75
Subclinical vasculitis as a potential mechanism to explain the heightened cardiovascular risk in rheumatoid arthritis. Circulation (2012) 0.75
Exploring the Crosstalk between Adipose Tissue and the Cardiovascular System. Korean Circ J (2017) 0.75
Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med (2005) 28.21
The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum (1987) 14.21
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis (2010) 10.03
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum (2008) 9.94
Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet (2002) 9.66
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum (2006) 8.78
Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation (2003) 6.62
Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension (2002) 6.06
High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum (2001) 5.87
Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med (1990) 5.65
Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation (1999) 5.62
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum (2006) 5.20
An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med (2010) 5.12
Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum (2005) 4.63
Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation (2003) 4.52
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum (2009) 3.58
Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum (2002) 3.53
Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis (2006) 3.48
Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med (2004) 3.36
Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum (2007) 3.34
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum (2011) 3.20
Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum (2003) 3.13
Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol (1999) 3.02
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA (2011) 3.02
Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum (2008) 2.93
Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. Arthritis Rheum (2008) 2.92
Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. Circulation (2008) 2.77
Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation (2000) 2.56
Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum (2007) 2.46
Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation (2002) 2.45
Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis (2010) 2.39
Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum (2004) 2.32
Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum (2007) 2.31
Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum (2003) 2.29
Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther (2006) 2.28
Methotrexate--how does it really work? Nat Rev Rheumatol (2010) 2.24
Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum (2008) 2.19
Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther (2008) 2.15
The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res (2007) 2.15
Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum (2005) 2.14
Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) (2011) 2.06
Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis. Arthritis Rheum (2005) 2.02
Mortality trends in rheumatoid arthritis: the role of rheumatoid factor. J Rheumatol (2008) 2.02
Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis (2011) 2.01
The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) (2009) 1.99
Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum (2006) 1.99
Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial). Ann Rheum Dis (2009) 1.90
Autoantibodies and the risk of cardiovascular events. J Rheumatol (2009) 1.89
Role of inflammation in atherosclerosis associated with rheumatoid arthritis. Am J Med (2008) 1.87
Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) (2009) 1.79
Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum (2008) 1.78
Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis (2010) 1.76
The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. Arthritis Rheum (2004) 1.61
Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation (2009) 1.61
Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol (2005) 1.59
Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol (2010) 1.59
Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum (2009) 1.56
Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) (2011) 1.55
Arterial stiffness in chronic inflammatory diseases. Hypertension (2005) 1.53
The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum (2008) 1.44
Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum (2008) 1.43
Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 1.42
Rheumatoid arthritis is an independent risk factor for multi-vessel coronary artery disease: a case control study. Arthritis Res Ther (2005) 1.38
Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine (2010) 1.37
CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation (2004) 1.36
HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med (2003) 1.36
Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) (2010) 1.34
Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One (2010) 1.32
Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol (2008) 1.29
Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int (2009) 1.27
Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol (2007) 1.24
Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum (2009) 1.23
A distinct profile of six soluble adhesion molecules (ICAM-1, ICAM-3, VCAM-1, E-selectin, L-selectin and P-selectin) in rheumatoid arthritis. Br J Rheumatol (1997) 1.13
Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol (2009) 1.13
Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness. Clin Exp Rheumatol (2006) 1.13
Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J (2008) 1.10
Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation. Arthritis Rheum (2003) 1.09
What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. Ann Rheum Dis (2007) 1.09
The expansion of CD4+CD28- T cells in patients with rheumatoid arthritis. Arthritis Res Ther (2003) 1.08
Joint swelling as a predictor of death from cardiovascular disease in a population study of Pima Indians. Arthritis Rheum (2001) 1.07
Outcome of rheumatoid arthritis in relation to age and rheumatoid factor at diagnosis. J Rheumatol (1993) 1.05
Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study. Arthritis Rheum (2007) 1.05
Effect of rheumatoid factor on mortality and coronary heart disease. Ann Rheum Dis (2009) 1.01
Methotrexate effects in patients with rheumatoid arthritis with cardiovascular comorbidity. Lancet (2000) 1.01
Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis. Expert Opin Investig Drugs (2008) 1.01
Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis (2006) 1.01
Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists. Rheumatology (Oxford) (2007) 0.99
The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol (2011) 0.97
Rheumatoid arthritis susceptibility genes associate with lipid levels in patients with rheumatoid arthritis. Ann Rheum Dis (2011) 0.95
Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab. Ann Rheum Dis (2010) 0.94
Prediction of mortality in rheumatoid arthritis based on disease activity markers. J Rheumatol (2005) 0.93
Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis (2008) 0.89
Augmentation index and large-artery remodeling in patients with longstanding rheumatoid arthritis compared with healthy controls. Semin Arthritis Rheum (2008) 0.89
Tumour necrosis factor alpha in severe congestive cardiac failure. Br Heart J (1993) 0.87
The role of immune complexes in atherogenesis. Angiology (2010) 0.87
Inflammatory cytokines, endothelial markers and adhesion molecules in rheumatoid arthritis: effect of intensive anti-inflammatory treatment. J Thromb Thrombolysis (2010) 0.86
The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists. Rheumatol Int (2006) 0.85
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet (2011) 4.67
Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA (2011) 3.97
Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol (2013) 3.25
Testing of low-risk patients presenting to the emergency department with chest pain: a scientific statement from the American Heart Association. Circulation (2010) 2.89
Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA (2013) 2.62
Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med (2008) 2.42
Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis (2010) 2.39
Appropriate cardiac cath lab activation: optimizing electrocardiogram interpretation and clinical decision-making for acute ST-elevation myocardial infarction. Am Heart J (2010) 2.33
Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis (2010) 1.76
Impact of noninsulin-dependent type 2 diabetes on carotid wall 18F-fluorodeoxyglucose positron emission tomography uptake. J Am Coll Cardiol (2012) 1.72
Targeting preschool children to promote cardiovascular health: cluster randomized trial. Am J Med (2012) 1.70
Effect of exercise treadmill testing and stress imaging on the triage of patients with chest pain: CHEER substudy. Mayo Clin Proc (2005) 1.69
Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging (2009) 1.66
Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial. Circulation (2012) 1.60
Authors' self-declared financial conflicts of interest do not impact the results of major cardiovascular trials. J Am Coll Cardiol (2013) 1.47
Emerging anti-inflammatory drugs for atherosclerosis. Expert Opin Emerg Drugs (2013) 1.43
Effects of proinflammatory cytokines on the growth, fate, and motility of multipotential neural precursor cells. Mol Cell Neurosci (2003) 1.42
Correlation between index electrocardiographic patterns and pre-intervention angiographic findings: insights from the HORIZONS-AMI trial. Catheter Cardiovasc Interv (2011) 1.41
Trends in the prevalence, awareness, treatment and control of high low density lipoprotein-cholesterol among United States adults from 1999-2000 through 2009-2010. Am J Cardiol (2013) 1.24
Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J (2004) 1.19
Optimizing 18F-FDG PET/CT imaging of vessel wall inflammation: the impact of 18F-FDG circulation time, injected dose, uptake parameters, and fasting blood glucose levels. Eur J Nucl Med Mol Imaging (2013) 1.14
Role of insulin resistance and hyperglycemia in the development of atherosclerosis. Am J Cardiol (2006) 1.14
RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol. Arthritis Care Res (Hoboken) (2011) 1.12
Serum cystatin C and increased coronary heart disease prevalence in US adults without chronic kidney disease. Am J Cardiol (2008) 1.08
The complementary roles of dynamic contrast-enhanced MRI and 18F-fluorodeoxyglucose PET/CT for imaging of carotid atherosclerosis. Eur J Nucl Med Mol Imaging (2013) 1.02
Prevalence and risk factors of carotid vessel wall inflammation in coronary artery disease patients: FDG-PET and CT imaging study. JACC Cardiovasc Imaging (2011) 1.01
Quality of life after PCI vs CABG among patients with diabetes and multivessel coronary artery disease: a randomized clinical trial. JAMA (2013) 1.01
Arterial and fat tissue inflammation are highly correlated: a prospective 18F-FDG PET/CT study. Eur J Nucl Med Mol Imaging (2014) 0.99
Impact of female sex on death and bleeding after fibrinolytic treatment of myocardial infarction in GUSTO V. Arch Intern Med (2007) 0.98
Spontaneous pneumomediastinum: is a chest X-ray enough? A single-center case series. Isr Med Assoc J (2008) 0.97
Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes. Diabetes Care (2006) 0.92
Risk for recurrent coronary heart disease and all-cause mortality among individuals with chronic kidney disease compared with diabetes mellitus, metabolic syndrome, and cigarette smokers. Am Heart J (2013) 0.92
The vulnerable plaque and acute coronary syndromes. Am J Med (2002) 0.91
Crushed clopidogrel administered via nasogastric tube has faster and greater absorption than oral whole tablets. J Interv Cardiol (2009) 0.88
Diabetes and aspirin: beware of underpowered negative trials. Nat Clin Pract Cardiovasc Med (2009) 0.88
Diabetes mellitus and acute coronary syndrome: lessons from randomized clinical trials. Curr Diab Rep (2012) 0.87
Assessing patient-reported outcomes and preferences for same-day discharge after percutaneous coronary intervention: results from a pilot randomized, controlled trial. Circ Cardiovasc Qual Outcomes (2013) 0.86
Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. Eur Heart J (2007) 0.85
Elevated homocysteine levels in patients with end-stage renal disease. Mt Sinai J Med (2005) 0.85
Long-term outcomes in non-diabetic patients with metabolic syndrome undergoing revascularization for multi-vessel coronary artery disease. Atherosclerosis (2007) 0.85
Association between physician follow-up and outcomes of care after chest pain assessment in high-risk patients. Circulation (2013) 0.84
Outcomes and care of patients with acute heart failure syndromes and cardiac troponin elevation. Circ Heart Fail (2013) 0.84
Outcomes in patients with chest pain evaluated in a chest pain unit: the chest pain evaluation in the emergency room study cohort. Am Heart J (2011) 0.84
Predictors of low clopidogrel adherence following percutaneous coronary intervention. Am J Cardiol (2011) 0.84
NSAIDs are associated with lower depression scores in patients with osteoarthritis. Am J Med (2013) 0.83
Long-term cardiovascular outcomes in patients with angina pectoris presenting with bundle branch block. Am J Cardiol (2011) 0.83
Biomarkers after risk stratification in acute chest pain (from the BRIC Study). Am J Cardiol (2012) 0.83
Diminished benefits of drug-eluting stents versus bare metal stents in patients with severe renal insufficiency. Nephron Clin Pract (2009) 0.82
Chronic kidney disease as a risk factor for acute coronary syndromes in patients presenting to the emergency room with chest pain. Transl Res (2012) 0.82
Relation of high-density lipoprotein cholesterol to mortality after percutaneous coronary interventions in patients with low-density lipoprotein <70 mg/dl. Am J Cardiol (2008) 0.82
Clustering of metabolic abnormalities among obese patients and mortality after percutaneous coronary intervention. Am J Cardiol (2011) 0.82
Promotion of cardiovascular health in preschool children: 36-month cohort follow-up. Am J Med (2013) 0.81
Awareness, treatment, and control of LDL cholesterol are lower among U.S. adults with undiagnosed diabetes versus diagnosed diabetes. Diabetes Care (2013) 0.81
Imaging outcomes in cardiovascular clinical trials. Nat Rev Cardiol (2009) 0.80
Is measuring C-reactive protein useful for guiding treatment in women > or = 60 years and men > or = 50 years of age? Am J Cardiol (2009) 0.80
Causes of death and re-hospitalization in cardiogenic shock. Acute Card Care (2007) 0.80
The Future REvascularization Evaluation in patients with Diabetes mellitus: optimal management of Multivessel disease (FREEDOM) trial: clinical and angiographic profile at study entry. Am Heart J (2012) 0.80
Aspirin use is associated with an improved long-term survival in an unselected population presenting with unstable angina. Clin Cardiol (2010) 0.79
Associations between routine coronary computed tomographic angiography and reduced unnecessary hospital admissions, length of stay, recidivism rates, and invasive coronary angiography in the emergency department triage of chest pain. J Am Coll Cardiol (2013) 0.79
Cardiovascular effects of selective COX-2 inhibition: is there a class effect? The International COX-2 Study Group. J Rheumatol (2006) 0.79
C-reactive protein predicts long-term mortality independently of low-density lipoprotein cholesterol in patients undergoing percutaneous coronary intervention. Am Heart J (2009) 0.78
Revascularization strategies in patients with diabetes. N Engl J Med (2013) 0.78
Prognostic significance of postprocedural sustained ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention (from the HORIZONS-AMI Trial). Am J Cardiol (2011) 0.78
Comparison of direct stenting with conventional stent implantation in acute myocardial infarction. Am J Cardiol (2011) 0.78
Cardiovascular disease in diabetics: pharmacology and revascularization. Mt Sinai J Med (2004) 0.78
Reply: Relevance of Indications for CABG in Evaluating the Effect of Dual Antiplatelet Therapy. J Am Coll Cardiol (2017) 0.77
Chagas disease as a mechanistic model for testing a novel hypothesis. Rev Soc Bras Med Trop (2008) 0.77
Malignancy validation in a United States registry of rheumatoid arthritis patients. BMC Musculoskelet Disord (2012) 0.77
Adverse cardiovascular effects of NSAIDs: driven by blood pressure, or edema? Ther Adv Cardiovasc Dis (2008) 0.77
Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients. Thromb Haemost (2007) 0.77
Time to welcome the elderly into clinical trials. Nat Clin Pract Cardiovasc Med (2008) 0.77
Meta-analysis of small trials: proceed with caution. Nat Clin Pract Nephrol (2008) 0.77
Optimal treatment of the diabetic patient with multivessel disease. Curr Cardiol Rep (2008) 0.77
Relation between the degree of procedural anticoagulation and complications after coronary stent implantation. Am J Cardiol (2003) 0.77
Balancing cardiovascular and gastrointestinal risks in patients with osteoarthritis receiving nonsteroidal anti‑inflammatory drugs. A summary of guidelines from an international expert group. Pol Arch Med Wewn (2016) 0.76
Noninvasive cardiovascular imaging in rheumatoid arthritis: current modalities and the emerging role of magnetic resonance and positron emission tomography imaging. Semin Arthritis Rheum (2011) 0.75
Acute coronary syndromes and diabetes mellitus: a winning ticket for prasugrel. Circulation (2008) 0.75
ACP Journal Club. Meta-analysis: Atorvastatin reduces CV events and increases new-onset diabetes in patients with coronary disease. Ann Intern Med (2013) 0.75
Non-steroidal anti-inflammatory drugs and the heart. Heart (2010) 0.75
Rapid complete reversal of systemic hypoperfusion after intra-aortic balloon pump counterpulsation and survival in cardiogenic shock complicating an acute myocardial infarction. Am Heart J (2011) 0.75
Reply: Underutilization of High-Intensity Statin Therapy After Hospitalization for Coronary Heart Disease: A Cause for Concern, But a Few Words of Caution. J Am Coll Cardiol (2015) 0.75
The PROSPECT of changing our approach to acute coronary syndromes. JACC Cardiovasc Imaging (2012) 0.75
Meta-analysis of small trials: proceed with caution. Nat Clin Pract Cardiovasc Med (2007) 0.75
Hypercholesterolemia is associated with visual field alterations detectable with computerized perimetry. Atherosclerosis (2007) 0.75
Stress testing and troponin in unstable coronary syndromes: the status trial-clinical outcomes and resource use. Am Heart Hosp J (2006) 0.75
The incremental value of troponin-I testing in patients with intermediate risk unstable angina. Clin Cardiol (2004) 0.75
LDL cholesterol response and statin adherence among high-risk patients initiating treatment. Am J Manag Care (2016) 0.75
Prognostic Significance of Post-CABG Enzyme Elevations. Anesth Analg (2017) 0.75
Polyarticular gout attacks following cerebrovascular accidents: is hemiparesis in fact protective? 2 cases and a review of the literature. J Clin Rheumatol (2010) 0.75
Preoperative Intraaortic Balloon Pump Improves Early Outcomes Following High-Risk Coronary Artery Bypass Graft Surgery: A Meta-Analysis of Randomized Trials and Prospective Study Design. J Invasive Cardiol (2017) 0.75
Characterizing young patients with diabetes and non-ST-segment elevation acute coronary syndromes. Diabetes Care (2007) 0.75
Left ventricular hypertrophy by electrocardiography and echocardiography in the African American Study of Kidney Disease Cohort Study. J Am Soc Hypertens (2012) 0.75
Does influenza vaccination influence cardiovascular complications? Expert Rev Cardiovasc Ther (2015) 0.75
Does PCI reduce the occurrence of 'hard' clinical endpoints in patients with stable coronary artery disease? Nat Clin Pract Cardiovasc Med (2005) 0.75
Faster publication isn't always better. Nat Clin Pract Cardiovasc Med (2007) 0.75
Does acetylsalicylic acid or warfarin affect the accuracy of fecal occult blood tests? J Gastroenterol Hepatol (2013) 0.75
Periprocedural myocardial enzyme elevation: prognostic implications for current practice. Curr Cardiol Rep (2012) 0.75
Failing to ENHANCE science. Nat Clin Pract Cardiovasc Med (2008) 0.75
Lumiracoxib, a highly selective COX-2 inhibitor. Expert Rev Clin Immunol (2005) 0.75